SOURCE: IO Circuit

October 28, 2011 07:30 ET Has Initiated Coverage of Mistral Ventures Inc.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO CIRCUIT

NEW YORK, NY--(Marketwire - Oct 28, 2011) - Mistral Ventures, Inc. (PINKSHEETS: MILV) announced today that it has reached an agreement with the inventor of a cold and flu medicine which has been in development for many years. Nature's Bioceuticals a wholly owned subsidiary of Mistral ventures, develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. gives you the "Ultimate Investors Edge." Traders who receive alerts first -- at the earliest stage of increasing price and liquidity -- could be positioned to generate significant profits. and their Early Bird Newsletter Alert provide in-depth fundamental and technical factors on stocks that trade in the Micro-Cap and Small Cap markets. To assists traders make more informed decisions and locate companies positioned to increase in volume, liquidity and price movement, we focus on extensively analyzing growth companies in some of the top sectors within these financial markets.

For more information, please visit

Other active stocks are AER Resources, Inc (PINKSHEETS: AERN) White Smile Global (OTCQB: WSML) and Converted Organics (OTCQB: COIN)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO NewsWire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information